ACTH and Sex Hormones: Cycle, Life Stage, and What Your Lab Result Actually Means

What ACTH Does and Why It Matters for Women

ACTH is a 39-amino-acid peptide secreted in bursts from the anterior pituitary. Each burst triggers the adrenal cortex to make cortisol, DHEA-S, and adrenal androgens. The hypothalamic-pituitary-adrenal (HPA) axis that governs this process is not a neutral system. Sex hormones shape it at every level, which means the axis behaves differently depending on where you are in your cycle, whether you are pregnant, or whether you have entered perimenopause.

Most reference ranges were built on studies that either used all-male cohorts or pooled men and women without accounting for menstrual phase at the time of blood draw. Comprehensive reviews of the HPA axis acknowledge this gap explicitly. That matters for you clinically: a result of 9 pg/mL might be perfectly appropriate for a luteal-phase draw on a healthy 32-year-old but could signal early secondary adrenal insufficiency in a postmenopausal woman who is not on hormone therapy and drew blood at 8 a.m.

How the HPA Axis Works in Brief

The hypothalamus releases corticotropin-releasing hormone (CRH). CRH tells the pituitary to release ACTH. ACTH tells the adrenal cortex to release cortisol. Cortisol feeds back negatively on both the hypothalamus and the pituitary to slow the whole cascade. Estrogen and progesterone insert themselves at multiple points in this loop.

Why Women Have a More Reactive HPA Axis

Animal and human data consistently show that estrogen increases CRH gene expression and sensitizes pituitary corticotroph cells to CRH stimulation, producing larger ACTH surges for a given stress load. This is one reason women report stress as a health concern at higher rates than men and show greater neuroendocrine responses to psychosocial stressors in controlled laboratory paradigms. It is not anxiety as a personality trait. It is biology.

ACTH Normal Range: What the Numbers Mean

The commonly cited reference interval for a morning plasma ACTH is 7-63 pg/mL, based on immunoradiometric and chemiluminescent assay platforms. Some labs report in pmol/L (divide pg/mL by 4.54 to convert).

Why "Normal" Is Not the Same as "Optimal"

In women's-health and longevity medicine contexts, a working framework used by practitioners at WomanRx distinguishes three zones:

| Zone | Morning ACTH (pg/mL) | Clinical signal | |---|---|---| | Low-normal concern | <10 | Secondary or tertiary adrenal insufficiency possible; check paired cortisol and pituitary MRI history | | Optimal | 10-40 | Adequate adrenal drive without chronic HPA over-activation | | High-normal concern | 41-63 | May reflect compensated primary adrenal insufficiency (paired cortisol low), chronic psychological stress, CRH excess, or assay interference | | Elevated | >63 | Requires workup: primary adrenal insufficiency, Cushing's disease (if cortisol is also elevated), ectopic ACTH syndrome |

No peer-reviewed guideline has formally adopted an "optimal" sub-range for women specifically. The distinction above is a clinical framework, not a published consensus statement. What is established: values consistently above 100 pg/mL in the presence of low cortisol confirm primary adrenal insufficiency, while suppressed ACTH (<5 pg/mL) alongside low cortisol points to a pituitary or hypothalamic cause.

Pre-Analytical Variables That Shift ACTH Before the Lab Even Runs the Sample

ACTH degrades rapidly at room temperature. Plasma must be collected in chilled EDTA tubes, centrifuged cold, and frozen within 15-30 minutes. Failure to cold-process a sample can falsely lower ACTH by 20-50%. If your result comes back unexpectedly low, ask your lab whether cold-chain protocol was followed.

Other variables that shift the result:

• Draw time: ACTH peaks between 6 and 8 a.m. And is roughly 50-80% lower by midnight (circadian nadir).
• Physical activity in the 30 minutes before the draw can raise ACTH acutely.
• Acute illness, surgery, or hypoglycemia each spike ACTH independently of adrenal disease.
• Glucocorticoid use (including inhaled or topical steroids at high doses) suppresses ACTH.

How the Menstrual Cycle Changes ACTH

ACTH is not stable across your cycle. The evidence for cycle-phase variation is modest but consistent enough to matter clinically.

Follicular Phase

Estrogen rises through the follicular phase and upregulates CRH receptor expression on pituitary corticotrophs, priming the axis for stronger ACTH output per unit of CRH. Basal ACTH concentrations in the early-to-mid follicular phase tend to sit at the lower end of the within-person range.

Ovulation and the LH Surge

The mid-cycle estrogen surge that triggers the LH peak may also produce a transient uptick in ACTH pulsatility. The clinical magnitude is small and unlikely to push a result outside the reference range, but it is one more reason to document cycle day on any lab requisition.

Luteal Phase

Progesterone rises after ovulation. Progesterone acts as a glucocorticoid receptor partial agonist, partially occupying cortisol receptors in the pituitary and hypothalamus. This blunts negative feedback, allowing ACTH pulse amplitude to increase without a corresponding rise in cortisol bioactivity. Studies using 24-hour urine free cortisol show a modest but measurable rise in the late luteal phase compared to the follicular phase. If you draw ACTH in the week before your period and the result sits in the high-normal range, a follicular-phase repeat draw is worth considering before pursuing further workup.

Premenstrual and PMDD Context

Women with premenstrual dysphoric disorder (PMDD) show blunted ACTH responses to CRH stimulation in the luteal phase compared to healthy controls, suggesting HPA axis dysregulation rather than simple cortisol excess. This is an important clinical nuance: PMDD is not "stress" manifesting as elevated ACTH. The HPA signature can look surprisingly flat.

Life-Stage Guide to ACTH Interpretation

Reproductive Years (Ages 18-40)

Cycle-phase documentation at draw is the single most actionable step. Ask your provider to note cycle day on the requisition. If ACTH is unexpectedly low or high, repeat the draw in the early follicular phase (days 2-5), fasted, before 9 a.m., with confirmed cold-chain handling.

Women in their reproductive years with adrenal insufficiency often present with fatigue, salt craving, irregular cycles, and hyperpigmentation (primary) or amenorrhea with low energy (secondary). The Endocrine Society's 2016 clinical practice guideline on adrenal insufficiency recommends the cosyntropin (synthetic ACTH) stimulation test as the gold standard for confirming insufficiency in ambiguous cases. A 30- or 60-minute post-stimulation cortisol below 18-20 mcg/dL is the accepted cut-off, though some authorities now use a threshold of 18 mcg/dL.

Trying to Conceive

Untreated adrenal insufficiency impairs fertility. Cortisol deficiency disrupts the hypothalamic GnRH pulse generator, leading to oligomenorrhea or amenorrhea and reducing implantation rates. If you are trying to conceive and have a history of adrenal insufficiency, your hydrocortisone dose needs active optimization before and during the conception attempt. Work with a reproductive endocrinologist alongside your endocrinologist.

Pregnancy

Pregnancy is the most dramatic physiological alteration of ACTH biology in the human lifespan.

The placenta synthesizes its own CRH (placental CRH or pCRH) in quantities that increase exponentially from the second trimester onward, with plasma CRH concentrations rising 1,000-fold by term. Pituitary ACTH production is partially suppressed by the negative feedback from rising placental cortisol, yet total circulating ACTH remains measurably elevated in the third trimester because pCRH drives additional ACTH release from extra-pituitary sites including the placenta itself. Standard reference ranges printed on lab reports are not valid during pregnancy. Interpreting a third-trimester ACTH result against a non-pregnant reference interval will produce false reassurance or false alarm.

Key pregnancy-specific points:

• Women with known adrenal insufficiency require increased hydrocortisone dosing, especially in the third trimester and during labor (stress dosing). ACOG and the Endocrine Society both recommend a structured sick-day and labor stress-dose protocol.
• Postpartum, the pCRH source disappears abruptly. Women with adrenal insufficiency are at risk of adrenal crisis in the days after delivery as the pituitary axis has been relatively suppressed during pregnancy. ACTH should be rechecked at the 6-week postpartum visit.
• Postpartum thyroiditis (which can occur in up to 10% of postpartum women) can alter cortisol metabolism and confound HPA interpretation; always check thyroid function concurrently.

Perimenopause

The menopause transition is a period of significant HPA axis restructuring. As estrogen falls, its stimulatory effect on CRH and pituitary sensitization diminishes. Studies in perimenopausal women show rising basal cortisol and flattening of the cortisol awakening response compared to premenopausal controls matched for age. Basal ACTH may drift upward as adrenal reserve becomes a more prominent determinant of cortisol output.

Practically, this means a perimenopausal woman drawing ACTH in the 45-55 age window may show ACTH in the 40-55 pg/mL range without any underlying pathology. Context matters: pair the result with a morning cortisol, check for clinical signs of excess (central weight gain, hypertension, purple striae, proximal muscle weakness) or deficiency (fatigue, salt craving, orthostatic symptoms, hyperpigmentation).

Hot flashes themselves activate the HPA axis acutely. A vasomotor symptom episode is associated with a transient cortisol spike measurable in saliva. If you are drawing ACTH in the perimenopausal window and had a hot flash within an hour of the blood draw, note it.

Post-Menopause

After menopause, adrenal DHEA and DHEA-S fall progressively regardless of ACTH levels, reflecting adrenal zone-specific aging. Basal ACTH may be normal or mildly elevated. The Menopause Society notes that HPA reactivity in post-menopausal women not using hormone therapy is altered compared to those who are, with systemic estradiol partially restoring pre-menopausal HPA sensitivity patterns.

Post-menopausal women starting or stopping hormone therapy (HT) should be aware that oral estrogen raises cortisol-binding globulin (CBG), which elevates total cortisol without changing free (active) cortisol. ACTH itself is not directly altered by exogenous estrogen at standard HT doses, but the paired cortisol interpretation changes: a total cortisol of 25 mcg/dL on oral estrogen does not mean the same thing as the same number off estrogen.

ACTH and Female-Specific Conditions

PCOS

Up to 25-50% of women with PCOS have adrenal androgen excess rather than (or alongside) ovarian androgen excess. In a subset of PCOS patients, exaggerated adrenal androgen responses to ACTH stimulation testing suggest dysregulated adrenal steroidogenesis. Basal ACTH is not usually elevated in PCOS, but the adrenal gland over-responds to each ACTH pulse with disproportionate DHEA-S and androstenedione output. A 17-hydroxyprogesterone level drawn at the same time as ACTH can help distinguish PCOS-associated adrenal excess from non-classical congenital adrenal hyperplasia (NCAH), which requires a cosyntropin stimulation test for definitive diagnosis.

Non-Classical Congenital Adrenal Hyperplasia (NCAH)

NCAH due to 21-hydroxylase deficiency is the most common adrenal enzyme defect in women, with a prevalence of approximately 1 in 100 to 1 in 1,000 depending on the population studied. Basal ACTH is often normal or mildly elevated. The diagnostic hallmark is a stimulated 17-hydroxyprogesterone above 10 ng/mL after cosyntropin. NCAH mimics PCOS clinically (irregular cycles, hirsutism, acne) and is frequently missed if ACTH and stimulation testing are not performed.

Hypothalamic Amenorrhea

Women with hypothalamic amenorrhea (HA), including those with relative energy deficiency in sport (RED-S), show chronically elevated cortisol and blunted ACTH pulsatility, a pattern distinct from primary or secondary adrenal insufficiency. The HPA axis is chronically activated by caloric deficit and psychological stress, suppressing the GnRH pulse generator. In HA, ACTH may be in the upper-normal range while cortisol is persistently elevated. Restoring energy availability is the treatment, not hydrocortisone replacement.

Thyroid Disease in Women

Hypothyroidism slows cortisol clearance and can raise total cortisol without changing ACTH. Hyperthyroidism accelerates cortisol metabolism and may modestly suppress ACTH. Always check TSH alongside ACTH when interpreting an ambiguous result. Postpartum thyroiditis, which affects an estimated 5-10% of postpartum women, can temporally distort HPA interpretation in the months after delivery.

When to Order ACTH and What to Order Alongside It

ACTH should not be ordered in isolation. The minimum useful panel for an initial workup of HPA dysfunction in women includes:

1. Plasma ACTH (morning, cold-chain, EDTA tube)
2. Serum cortisol (same draw, morning)
3. Urine free cortisol (24-hour) if Cushing's syndrome is in the differential
4. DHEA-S
5. TSH and free T4
6. Comprehensive metabolic panel (to flag electrolyte changes suggestive of mineralocorticoid deficiency)

If results are equivocal, the Endocrine Society guideline recommends the 250-mcg cosyntropin stimulation test as the definitive next step for confirming adrenal insufficiency. A 1-mcg (low-dose) cosyntropin test is sometimes preferred in suspected secondary adrenal insufficiency to avoid masking a subtle deficit, though this remains debated in the literature and is not universally available.

The direct quote from the 2016 Endocrine Society guideline: "We suggest using the 250-mcg (standard-dose) cosyntropin stimulation test for confirming the diagnosis of adrenal insufficiency".

Evidence Gaps: What We Do Not Know About ACTH in Women

Be candid about the limits. Most ACTH reference intervals were established in studies enrolling predominantly male or mixed-sex populations without recording menstrual cycle phase. A 2018 systematic analysis of endocrine reference intervals found that fewer than 30% of studies stratified results by sex, and nearly none stratified by cycle phase.

What is extrapolated rather than directly studied:

• The magnitude of luteal-phase ACTH elevation in healthy women of reproductive age has been described in small studies (<50 participants in most). No large normative study exists.
• The effect of gender-affirming hormone therapy on ACTH reference intervals is not yet characterized in published guidelines.
• Whether the "optimal" 10-40 pg/mL sub-range has outcomes data in women specifically is unknown. It is a clinical-consensus framework, not an evidence-based target with morbidity endpoints.

This honesty is clinically useful: if your result sits in the 40-62 pg/mL range and you are a perimenopausal woman who drew blood after a night of poor sleep, the result likely reflects physiological context, not disease.

Who Should Prioritize ACTH Testing

Consider ACTH testing if you have:

• Unexplained fatigue, salt craving, or orthostatic dizziness (possible adrenal insufficiency)
• Skin hyperpigmentation in sun-exposed areas and skin creases (primary adrenal insufficiency)
• Central weight gain, easy bruising, proximal muscle weakness, or difficult-to-control hypertension (possible Cushing's syndrome or disease)
• PCOS with disproportionate DHEA-S elevation or hirsutism not explained by ovarian androgens
• Irregular or absent periods with chronically elevated stress (hypothalamic amenorrhea workup)
• A personal or family history of autoimmune disease, given the association with autoimmune Addison's disease
• Prior or current use of high-dose glucocorticoids (risk of secondary adrenal insufficiency)

ACTH testing is less likely to add value if you have:

• A chief complaint of general fatigue in the absence of any additional clinical signs
• Already-confirmed hypothyroidism that is not yet treated (treat the thyroid first, then reassess)
• A recent acute illness, as ACTH will be non-specifically elevated

Pregnancy, Lactation, and Contraception Considerations

Pregnancy

ACTH testing during pregnancy requires pregnancy-specific reference intervals, which most commercial labs do not provide. Do not use non-pregnant reference ranges to interpret a result drawn during the second or third trimester. Women with known adrenal insufficiency on hydrocortisone replacement should not discontinue or reduce medication during pregnancy. Hydrocortisone is the preferred glucocorticoid in pregnancy because it is substantially inactivated by placental 11-beta-HSD2 before crossing to the fetus; fetal exposure is estimated at roughly 10% of the maternal dose.

For women with Cushing's disease (pituitary ACTH excess), pregnancy management is complex. Metyrapone is sometimes used in the second trimester when surgery is not possible, though data are limited to case series. Cabergoline and pasireotide are not recommended in pregnancy due to insufficient human safety data.

Postpartum and Lactation

Women with primary or secondary adrenal insufficiency on hydrocortisone can breastfeed safely. Hydrocortisone does transfer into breast milk, but at standard replacement doses (15-20 mg/day total), milk concentrations are low and systemic infant exposure is considered clinically insignificant. Timing the morning dose after the first morning feed, rather than before, further reduces infant exposure.

ACTH testing in the postpartum period should account for the abrupt withdrawal of placental CRH: the HPA axis may take 6-12 weeks to re-establish normal pulsatility after delivery, and women with borderline adrenal reserve may decompensate in the immediate postpartum period even if they were asymptomatic during pregnancy.

Contraception

No direct contraception requirement applies to ACTH testing itself. However, combined oral contraceptive pills (COCPs) raise CBG, which elevates total cortisol. This can make the paired cortisol result harder to interpret. If you are on a COCP and your ACTH-cortisol pair looks discordant, a free or late-night salivary cortisol adds useful context. Stopping the COCP for 4-6 weeks before a formal HPA evaluation (if clinically safe to do so) will normalize CBG and simplify interpretation.